Skip to main navigation
Theratechnologies Inc. Theratechnologies Inc.

    About

  • About
    • About Us
    • Board of Directors
    • Leadership Team
    • Scientific Consultants & Advisors
    • Awards
    • Corporate Responsibility

    • Medicines & Pipeline

  • Medicines & Pipeline
    • Medicines
      • Trogarzo®
      • EGRIFTA SV®
    • Pipeline & Science
      • HIV
        • F8 in HIV-Associated Excess Abdominal Fat
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Hepatology
        • Tesamorelin for the Potential Treatment of NASH
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Oncology
        • SORT1+ Technology™
        • Sudocetaxel zendusortide (TH1902)
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Expanded Access Policy
      • Grants/ISRs/IITs

    • IR Nav

  • Investors
    • Overview
    • News, Events & Presentations
      • Press Releases
      • Company Announcements
      • Events
      • Corporate Presentations
    • Stock Information
      • Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • SEDAR Filings
      • Financial Reports
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Investor Resources
      • Contact IR
      • FAQs

    • Careers

  • Careers

    • Contact Us

  • Contact Us
  • en
    • en
    • fr

    • btn Alerts

  • Sign up for Email Alerts

Social icons

News

Investors

IR Nav

  • Overview
  • News, Events & Presentations
    • Press Releases
    • Company Announcements
    • Events
    • Corporate Presentations
  • Stock Information
    • Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • SEDAR Filings
    • Financial Reports
  • Corporate Governance
    • Documents & Charters
    • Board of Directors
    • Leadership Team
    • Committee Composition
  • Investor Resources
    • Contact IR
    • FAQs

Stock

Prices shown in CAD

Dec 22, 2024 1:30 AM EST

btn Stock

Learn More

IR Tools

  • Email Alerts
  • Contact IR
  • RSS Feeds

Specific Billing J-Code Issued for Trogarzo® by Center for Medicare and Medicaid Services

Nov 08, 2018
PDF Version
Supporting Materials:
Specific Billing J-Code Issued for Trogarzo® by Center for Medicare and Medicaid Services 243.4 KB
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Trogarzo® (ibalizumab-uiyk) injection has been assigned a specific J-Code. The new code will come into effect as of January 1, 2019.

Headquarters

Theratechnologies inc.
2015 Peel Street, 11th Floor
Montréal, Québec
Canada H3A 1T8
Phone: 514 336-7800
Fax: 514 331-9691

European Headquarters

Theratechnologies Europe Limited
1st Floor, 12 Duke Lane Upper
Royal Hibernian Way
DUBLIN
Dublin 2
Ireland D02 DX07
Phone: +353 1 215 0650
europe@theratech.com

Investor Relations

Philippe Dubuc
Senior Vice President and Chief Financial Officer
Phone: +1-438-315-6608
ir@theratech.com

US Headquarters

Theratechnologies U.S., Inc.
101 Hudson Street
21st Floor
Jersey City, New Jersey 07302

Main Nav

  • Home
  • About
  • Medicines & Pipeline
  • Investors
  • Careers
  • Contact Us
©2024 - Theratechnologies Inc.

Legal Nav

  • Terms of Use
  • Privacy

Search

Theratechnologies